Moderna Inc (MRNA.O) stated on Saturday it has entered into an settlement with Samsung Biologics Co Ltd(207940.KS), a deal which is able to enable the South Korean biopharmaceutical agency to provide the U.S. firm’s mRNA vaccine.
Moderna intends to provide these vaccines to markets exterior of the United States beginning within the third quarter of 2021, it stated in a press launch .
The agency additionally signed two memoranda of understanding (MOU) with South Korea’s authorities, one with Korea National Institute of Health (KNIH) and one other with Ministry of Trade and Industry and Energy of the Republic of Korea (MOTIE).
South Korea has secured entry to 40 million doses of Moderna’s COVID-19 vaccine, Moderna stated.
“We will proceed to discover choices for establishing potential native manufacturing alternatives in South Korea,” Moderna’s Chief Executive Stéphane Bancel said.
Read all of the Latest News, Breaking News and Coronavirus News right here
